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Abstract
Insulin-like growth factor-1 receptor (IGF-1R) comprises two subunits, including a ligand binding domain on extra- cellular
IGF-1Ra and a tyrosine phosphorylation site located on IGF-1Rb. IGF-1R is over-expressed by orbital fibroblasts in the
autoimmune syndrome, Graves’ disease (GD). When activated by IGF-1 or GD-derived IgG (GD-IgG), these fibroblasts
produce RANTES and IL-16, while those from healthy donors do not. We now report that IGF-1 and GD-IgG provoke IGF-1R
accumulation in the cell nucleus of GD fibroblasts where it co-localizes with chromatin. Nuclear IGF-1R is detected with anti-
IGF-1Ra-specific mAb and migrates to approximately 110 kDa, consistent with its identity as an IGF-1R fragment. Nuclear
IGF-1R migrating as a 200 kDa protein and consistent with an intact receptor was undetectable when probed with either
anti-IGF-1Ra or anti-IGF-1Rb mAbs. Nuclear redistribution of IGF-1R is absent in control orbital fibroblasts. In GD fibroblasts,
it can be abolished by an IGF-1R-blocking mAb, 1H7 and by physiological concentrations of glucocorticoids. When cell-
surface IGF-1R is cross-linked with
125I IGF-1,
125I-IGF-1/IGF-1R complexes accumulate in the nuclei of GD fibroblasts. This
requires active ADAM17, a membrane associated metalloproteinase, and the phosphorylation of IGF-1R. In contrast, virally
encoded IGF-1Ra/GFP fusion protein localizes equivalently in nuclei in both control and GD fibroblasts. This result suggests
that generation of IGF-1R fragments may limit the accumulation of nuclear IGF-1R. We thus identify a heretofore-
unrecognized behavior of IGF-1R that appears limited to GD-derived fibroblasts. Nuclear IGF-1R may play a role in disease
pathogenesis.
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Introduction
The insulin-like growth factor-1 receptor (IGF-1R) is a
membrane spanning protein through which IGF-1 and IGF-2
exert many of their actions [1]. It comprises two subunits [1,2].
The ligand binding, extracellular domain of IGF-1R is located on
IGF-1Ra while the membrane-spanning b subunit contains the
tyrosine phosphorylation site necessary for canonical signal
initiation. IGF-1R functions to support cell growth [3] and
transformation [4]. Its activation can lead to the generation of
anti-apoptotic signals including several cell-survival proteins [5,6].
Besides its importance in the regulation of metabolism, IGF-1R
can determine the quality and magnitude of immune responses
and may play a role in the pathogenesis of autoimmunity [7]. Most
studies examining IGF-1R function have focused on the activation
of orthodox kinase signaling pathways [1,8]. In addition to their
activities on the cell membrane surface, several other transmem-
brane tyrosine kinase receptors have been found to translocate to
the cell nucleus and in so doing influence gene expression [9,10].
But intracellular trafficking of the IGF-1R to the cell nucleus has
not been reported previously.
Graves’ disease (GD) is an autoimmune process where the
thyroid gland becomes enlarged and over-active [11]. Activating
IgGs directed against the thyrotropin receptor (TSHR), termed
thyroid-stimulating antibodies (TSI) or GD-derived IgG (GD-
IgG), drive thyroid gland over-activity and accelerated tissue
metabolism through cyclic AMP generation [12]. In addition,
connective tissues in the orbit become activated, inflamed, and
undergo substantial remodeling in a process known as thyroid-
associated ophthalmopathy (TAO) [13,14]. Reports have ap-
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TSI and the clinical activity of TAO [15]. Although conceptually
appealing, participation of these antibodies in the pathogenesis of
TAO has yet to be firmly established [16].
A key aspect of GD concerns the recruitment of T lymphocytes
and other pro-inflammatory cells to involved anatomic sites
[17,18]. We recently reported that fibroblasts from patients with
GD become activated by their GD-IgG and synthesize two
powerful T lymphocyte chemoattractants, IL-16 and RANTES
[19]. This response is mediated through over-expressed IGF-1R
[20]. In contrast, control fibroblasts from donors without known
autoimmune disease fail to exhibit this response. We postulate that
GD-IgG activation of orbital fibroblasts in GD results in tissue
infiltration with T and B lymphocytes [18,21,22], cells that also
over-express IGF-1R in GD [23,24]. TSHR and IGF-1R form a
physical and functional complex in GD fibroblasts and thyroid
epithelial cells [25]. This may account for at least some of the
tissue responses to TSH. The activation of Erk by TSH can be
attenuated with IGF-1R-blocking antibodies [25]. Thus it is
possible that GD-IgG targeting of not only TSHR but also IGF-
1R plays a pathological role in GD. Besides IL-16 and RANTES,
GD fibroblasts from the orbit treated with IGF-1 and GD-IgG also
generate higher levels of hyaluronan than untreated controls [26].
Here we report that the higher level of cell surface-displayed
IGF-1R on TAO fibroblasts is associated with the accumulation of
an IGF-1R fragment in the cell nucleus. This trafficking of
endogenous IGF-1R does not occur in fibroblasts from healthy
donors. It is completely blocked by 1H7, an anti-IGF-1R blocking
antibody, and is dependent on the activity of ADAM17, a
metalloproteinase involved in the shedding of surface proteins
[27,28]. It appears that nuclear trafficking of IGF-1R represents a
previously unrecognized phenotypic signature peculiar to orbital
fibroblasts from patients with TAO that may therefore underlie
GD-specific responses to IGF-1 and GD-IgG.
Results
IGF-1 and GD-IgG provoke nuclear accumulation of IGF-
1Ra in GD-Fibroblasts
Cultured human fibroblasts express IGF-1R [29]. Orbital
fibroblasts from patients with TAO are skewed toward the IGF-
1R
+ phenotype and levels of the receptor protein are increased
compared to those from healthy controls [20,25]. This increased
receptor density exhibits durability over many population
doublings and serial passages in vitro. When GD orbital fibroblasts
or those from control donors are treated with IGF-1 (10 nM), loss
of cell-surface IGF-1R can be detected by flow cytometric analysis.
The magnitude of this reduction is appreciable: IGF-1 lowered the
fraction of cells expressing the receptor by 46%. It could be
blocked by lowering the temperature of the cells from 25uCt o4 uC
and by treating cultures with dexamethasone (10 nM) (data not
shown).
To assess IGF-1R trafficking from the surface of orbital
fibroblasts, cells were stained and subjected to confocal immuno-
fluorescense microscopy. Chromatin was stained with propidium
iodide (PI, red). IGF-1Ra was detected using a FITC conjugated
secondary antibody against rabbit polyclonal anti-IGF-1Ra
antibody (green) (Fig. 1A). IGF-1R staining localized on the
plasma membrane and in the central cytoplasm of untreated
control and GD fibroblasts. In striking contrast to the pattern in
untreated cells, those incubated with IGF-1 accumulated IGF-1R
in the cell nucleus (appearing yellow) while the intensity of the
cytoplasmic signal was reduced (Fig. 1A). Eighty percent of nuclei
in IGF-1-treated GD fibroblasts exhibited change to yellow color.
The receptor remained localized primarily in the cytosol of IGF-1-
treated control fibroblasts while only 5% were yellow in color.
IGF-1R also appears to translocate from cytosol to the nucleus in
response to GD-IgG (15 mg/ml) of GD fibroblasts, a response that
was absent in control fibroblasts (Fig. 1B). Thus, the effects of IGF-
1 resemble those of GD-IgG. Control IgG had no effects on IGF-
1R localization (Fig. 2B). Dexamethasone (10 nM) could block the
effect of IGF-1 on nuclear accumulation of IGF-1Ra (Fig. 1C).
This steroid concentration is associated with near-maximal
responses in human fibroblasts [30]. The IGF-1R blocking
monoclonal antibody, 1H7 (5 mg/ml), which precludes receptor
activation [31], was added to GD fibroblasts cultures without or
with GD-IgG. As Fig. 1D demonstrates, 1H7 completely
attenuated the nuclear accumulation of IGF-1Ra. Thus, it would
appear that the effects of GD-IgG on IGF-1R localization are
mediated directly through IGF-1R itself. This is confirmed by the
ability of Des 1–3 IGF-1 to mimic the effects of IGF-1 and GD-IgG
(data not shown). That growth factor analogue acts very
specifically on the receptor and has relatively low affinity for
IGF-1 binding proteins [32]. The images in the right sided panels
of Fig. 1A demonstrate the impact of IGF-1 on the distribution of
IGF-1Rb (green). Unlike IGF-1Ra, IGF-1Rb fails to accumulate
in the nucleus but rather is dispersed peripherally before and
following IGF-1 treatment.
IGF-1R protein accumulates in GD fibroblast nuclei
following treatment with IGF-1 or GD-IgG as determined
by subcellular fractionation
We next determined whether the treatment of GD fibroblasts
with IGF-1 resulting in the redistribution of IGF-1R by confocal
microscopy led to nuclear accumulation of receptor protein as
assessed following subcellular fractionation. Fibroblasts treated
with nothing (control) or IGF-1 for 16 h were then subjected to
Western immunoblot analysis. The level of nuclear IGF-1R
migrating as a 110 kDa band was substantially increased following
treatment while a reciprocal loss was detected from the cytosol
(Fig. 2A). Moreover, GD-IgG like IGF-1 increased nuclear content
of IGF-1R in GD fibroblasts but had no effect in control cells
(Fig. 2B). IGF-1R and the insulin receptor (IR) share both
structural and functional similarities. To rule out cross-reactivity
between these two proteins and to determine whether the effects of
IGF-1 on IGF-1R were specific, monolayers were treated with
insulin (15 mg/ml) for 16 hours. Nuclear IGF-1Ra levels were
unaffected by insulin in fractionated cells (Fig. 2C). IR levels were
invariant with respect to treatment with either insulin or IGF-1
(data not shown). Thus, the effects of IGF-1 on nuclear IGF-1R
abundance appear to be specific.
IGF-1R detected in the nucleus could comprise intact receptor
protein with an expected mw of approximately 200 kDa or a
fragment containing the epitope recognized by anti-IGF-1Ra.A s
the Western blot analysis in Fig. 2D demonstrates, while the intact
receptor was detected in the cytosolic fraction, this 200 kDa IGF-
1R could not be detected by immunoblot analysis in the nucleus.
This analysis utilized an anti-IGF-1Rb monoclonal antibody and
thus both 110 kDa and 200 kDa bands were absent in the nuclear
compartment while both were abundant in the cytosol. Coupled
with our inability to detect IGF-1Rb associated with the nucleus
using confocal microscopy, it would appear that the receptor
fragment accumulating in the nucleus does not contain the epitope
identified by anti-IGF-1Rb.
We next determined whether the translocation of IGF-1Ra was
dependent on IGF-1R tyrosine phosphorylation. NVP-AEW541 is
a novel, pyrrolo [2,3-d]pyrimidine derivative, and highly-selective
inhibitor of IGF-1R kinase activity [33,34]. When added with
IGF-1 Receptor and Graves’ Disease
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(Fig. 3A). Moreover, the agent blocked nuclear co-localization
with chromatin (Fig. 3B) and the accumulation of IGF-1R in the
nucleus (Fig. 3C). This finding suggests that IGF-1R phosphor-
ylation is essential for nuclear trafficking.
Cell-surface [
125I] IGF-1R complexes translocate to the
nuclei of IGF-1-treated GD fibroblasts
Studies examining endogenous IGF-1R localization, as de-
scribed above, relied on specific monoclonal antibodies directed
against this protein. We next examined nuclear translocation with
an additional approach, one that was independent of antibodies.
[
125I]-IGF-1 was cross-linked to cell surface IGF-1R displayed on
GD fibroblasts. After 16 hr, fibroblasts were subjected to
subcellular fractionation. As Fig. 2E demonstrates, IGF-1-bound
radioactivity accumulates in the nuclei of GD fibroblasts when
cross-linked to IGF-1R with a cell-permeable agent (DSS). In
contrast, when an impermeable cross-linking compound (BS) was
used, virtually no nuclear radioactivity could be detected.
Substantially less [
125I]-IGF-1 localized in nuclei of control
fibroblasts than that detected in the GD fibroblasts. These findings
suggest strongly that IGF-1Ra detected in the nuclei of IGF-1-
treated GD fibroblasts originated at the cell surface.
Activity of ADAM17 may be essential to nuclear
translocation of cell-surface- associated IGF-1R
The divergence between nuclear accumulation of endogenous
IGF-1Ra in control and GD fibroblasts suggests that fundamental
aspects of IGF-1R protein trafficking/signaling might differ in the
two cell types. Because nuclear IGF-1R following IGF-1 treatment
appears to represent a fragment of the receptor lacking the epitope
recognized by anti-IGF-1Rb, we wondered whether translocation
might involve the actions of cell surface proteases. One such
candidate is ADAM17, a transmembrane glycoprotein metallo-
proteinase, involved in interactions with multiple substrates
[27,28,35]. GD fibroblasts express high levels of ADAM17 mRNA
as do control fibroblasts (control, 0.9860.095 vs TAO, 1.060.08
normalized fold-change, NS). To explore its potential involvement
Figure 1. Confocal imaging of IGF-1R reveals nuclear accumulation in TAO fibroblasts following treatment with either IGF-1 or GD-
IgG. (A) untreated (control, upper panels) or IGF-1 (10 nM) (lower panels) for 16 h. reveals localization of IGF-1Ra (green) as indicated by the yellow
overlay nuclei in GD fibroblasts. Chromatin was stained by PI (red). Control fibroblasts failed to respond. The images labeled IGF-1Rb (green)
demonstrate an absence of effects with IGF-1 on nuclear accumulation. Scale bar, 25 mm. (B) IGF-1Ra (green) co-localizes in the PI-stained nuclei
(yellow overlay) following treatment with GD-IgG (15 mg/ml) in GD but not in control fibroblasts. (C) Dexamethasone (10 nM) attenuates the nuclear
accumulation of IGF-1Ra (D) as does the IGF-1R-blocking mAb, 1H7 (5 mg/ml). These experiments have been performed 4 times.
doi:10.1371/journal.pone.0034173.g001
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ADAM17, was added to culture medium alone or in combination
with IGF-1. This agent completely blocked IGF-1R accumulation
in the nucleus (Fig 4A and 4B). ADAM 17 expression was then
knocked down with a specific siRNA, a maneuver that also
significantly diminished nuclear IGF-1Ra accumulation (Fig. 5).
In aggregate, our findings suggest that ADAM17 might play a role
in the nuclear translocation of fragmented IGF-1R.
Equivalent nuclear accumulation of virally encoded IGF-
1Ra/GFP fusion protein in GD and control fibroblasts
If less receptor fragmentation in control fibroblasts accounts for
the absence of IGF-1Ra accumulation in the nucleus of control
fibroblasts, expressing the free subunit in control and GD
fibroblasts should result in equivalent nuclear IGF-1Ra.T o
directly test this hypothesis, a virally encoded IGF-1Ra/GFP
fusion protein was cloned and transfected into fibroblasts. A dose-
dependent increase in GFP- IGF-1Ra fusion protein can be
detected by subjecting cell lysates to Western blot analysis (Fig. 6A).
Strong co-localizing nuclear signals for both GFP and IGF-1Ra
were detected in both control and GD fibroblasts (Fig. 6B).
Moreover, accumulation of the fusion protein was identical in
control and GD fibroblasts. This result suggests that the nuclear
translocation of endogenous IGF-1Ra may be limited by receptor
fragmentation.
Discussion
Several receptors initially thought to function at the cell surface
have been subsequently found to traffic to the cell nucleus [36].
These include epidermal growth factor receptor (EGFR) [37],
fibroblast growth factor receptor (FGFR) [38,39], and Notch-1
[40]. EGFR can function in the nucleus as a transcription factor
[37]. Cells and tissues with prominent nuclear EGFR localization
exhibit accelerated proliferation. Moreover, EGF increases
content of phosphorylated EGFR within the nucleus. Nuclear
EGFR translocation following irradiation is tied to DNA repair
and activation of DNA-dependent kinase [41]. A transactivation
domain harbored by EGFR acts at specific target gene promoter
sequences, such as the one identified on the cyclin D1 gene [37].
Like IGF-1R, EGFR exhibits intrinsic tyrosine kinase activity [42].
FGFR1 translocates to the nucleus following endocytosis provoked
by FGF, through mechanisms linked to the activities of E-cadherin
[39]. Balance between these two proteins on the surface of
epithelial cells appears to be crucial to the nuclear accumulation of
FGFR1. Once in the nucleus, FGFR1 interacts with the
transcription co-activator, CREB-binding protein [43]. Unlike
the actions of FGFR1 mediated at the plasma membrane, those
occurring in nuclei of neural progenitor cells appear independent
of endogenous tyrosine kinase activity. Rather, the FGFR1/CBP
complex recruits RNA polymerase II and enhances histone
acetylation [43]. From the findings reported here, it would appear
Figure 2. IGF-1R protein differentially accumulates in the nuclei of TAO orbital fibroblasts and derives from the fibroblast surface.
(A) Western blot analysis of nuclear and cytoplasmic IGF-1Ra in GD orbital fibroblasts before and following IGF-1 (10 nM) treatment for 16 h. Cells
were subjected to subcellular fractionation as described in ‘‘Methods’’ and membranes were probed with anti-IGF-1Ra, stripped, and re-probed with
anti-Grb2 (cytoplasmic) and anti-c-Jun (nuclear) Abs. (B) Nuclear IGF-1Ra content in GD and control orbital fibroblasts before or following treatment
with either IGF-1 (10 nM) or GD-IgG (15 mg/ml) for 16 hours. (C) Insulin fails to alter the nuclear content of IR or IGF-1Ra in GD orbital fibroblasts. Cells
were treated with nothing or insulin (15 mg/ml) for 16 hrs. They were subjected to subcellular fractionation and Western blot analysis. (D) IGF-1Rb
(98 kDa) and the intact receptor (200 kDa) are undetectable in the nucleus under basal and IGF-1-treated conditions. (E) Control and GD fibroblasts
were subjected to
125I-IGF-1 cross-linking with either the cell-impermeable agent, BS, or the cell permeable agent, DSS. They were then treated with
IGF-1. Nuclei were separated as described in ‘‘Methods’’ and subjected to quantification of radioactivity. Results are representative of three
experiments performed.
doi:10.1371/journal.pone.0034173.g002
IGF-1 Receptor and Graves’ Disease
PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e34173that IGF-1R closely resembles Notch-1, another transmembrane
protein that signals through intermediate proteins at the cell
surface but can also traffic to the nucleus as a protease-generated
cleavage fragment [40]. The cross linking studies here suggest that
125I IGF-1 nuclear IGF-1R also translocates from the cell surface
(Fig. 5). It would appear that the nuclear IGF-1R is not
synthesized de novo, since cycloheximide fails to block nuclear
accumulation of the receptor provoked by IGF-1 or GD-IgG (data
not shown). Previous studies by Vecchione et al [44] have
demonstrated IGF-1Rb trafficking to the proteosome where the
protein can undergo ubiquination. This process is mediated
through the Grb10 adapter protein which inhibits IGF-1R-
dependent signaling [45] and serves to promote the interaction
between IGF-1Rb and Nedd4, a ubiquitin protein ligase, through
the formation of a Grb10/DNedd4IGF-1Rb complex [46]. Both
proteosomal and lysosomal pathways are involved in IGF-1R
degradation [44]. Thus while the turnover of the receptor has
been characterized, the potential for its trafficking to the nucleus
has not been reported previously. Examination of its primary
structure reveals a single potential nuclear localization sequence
ERKRRD located in the amino terminus of IGF-1Rb. It remains
uncertain whether that sequence is involved in IGF-1R trafficking.
It is notable that IR can also be detected, albeit at low levels, in
GD fibroblast nuclei (Fig. 2C). This finding is congruent with a
recent report demonstrating that IR and IR substrate-1 associate
with the nuclear matrix of insulin-treated osteoblast-like UMR-
106 cells [47].
The current finding may have substantial clinical implications.
Orbital fibroblasts from patients with GD exhibit a unique
phenotype. Their distinctive characteristics may account for the
susceptibility of the orbit to TAO. They express an unusual gene
profile especially when treated with inflammatory cytokines [48].
They exhibit biosynthetic activities such as the exaggerated
production of the glycosaminoglycan, hyaluronan [49,50] and
the exaggerated induction by cytokines of prostaglandin endoper-
oxide H synthase-2, the inflammatory cyclooxygenase [50–52].
TAO fibroblasts represent two distinct populations on the basis of
their display of CD34 [53]. CD34
+ fibroblasts appear to derive
from circulating bone marrow fibrocytes which can differentiate
into orbital fat cells. Recognizing that they over-express IGF-1R
and exhibit divergent receptor trafficking and signaling could aid
in developing targeted therapies.
To the best of our knowledge, the current studies are the first to
demonstrate IGF-1R fragmentation into differentially behaving
proteins and nuclear translocation. Moreover, these findings
Figure 3. IGF-1Rb phosphorylation may play an essential role in
the nuclear translocation of IGF-1Ra in GD orbital fibroblasts.
(A) NVP-AEW-541, a specific tyrosine kinase inhibitor blocks IGF-1R
phosphorylation (B) NVP-AEW-541 blocks nuclear IGF-1Ra accumula-
tion. GD orbital fibroblasts were treated as indicated and stained with
anti-IGF-1Ra Ab (green) and counterstained with PI. (C) Western blot
analysis of nuclear proteins from GD orbital fibroblasts treated with
nothing, IGF-1, NVP-AEW-541, or the combination and probed with
anti- IGF-1Ra and anti-c-jun Abs. The findings are representative of
three experiments performed.
doi:10.1371/journal.pone.0034173.g003
Figure 4. ADAM 17 appears to play a critical role in nuclear accumulation of IGF-1Ra. (A) GD orbital fibroblasts express ADAM 17 protein
as assessed by Western blot. (B). TAPI-1, a specific inhibitor of ADAM17 activity, blocks the nuclear accumulation of IGF-1Ra provoked by IGF-1 in GD
orbital fibroblasts. (C) Quantification of nuclear grey color signal intensity. Each bar in the histogram represents the mean 6 SD of ten nuclei
randomly chosen for each treatment group. *, p,0.05 vs IGF-1; **, p,0.01 vs control, n=3 independent determinations.
doi:10.1371/journal.pone.0034173.g004
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transfected with control siRNA or that specifically targeting ADAM 17. Some were left untreated while others were treated with IGF-1. Cells were fixed
and stained with anti-IGF-1Ra Ab/Orgeon Green anti-rabbit Ab. Quantification of nuclear intensity was conducted so that each column represents the
mean of ten randomly chosen nuclei 6 SD. *, p,0.002 vs control; **, p,0.01 vs IGF-1. n=3 independent determinations. (Inset) Adam17 siRNA or
control siRNA was transfected into GD fibroblasts, cells were lysed, and proteins subjected to Western blot analysis by probing with anti-ADAM 17 Ab,
stripping the membrane and incubating with anti-b-actin.
doi:10.1371/journal.pone.0034173.g005
Figure 6. Virally encoded IGF-1Ra-GFP fusion protein expression in GD and control orbital fibroblasts. (A) Expression of the
adenovirus-encoded IGF-1Ra–GFP fusion protein can be detected by Western blot analysis probed by both anti-GFP and anti-IGF-1Ra.( B) IGF-1Ra-
GFP fusion protein accumulates in the nuclei of both control and GD orbital fibroblasts, as assessed by Western blot analysis following subcellular
fractionation of nuclear protein. IGF-1 treatment fails to alter this pattern. These studies are representative of 5 experiments involving expression of
virally encoded IGF-1Ra.
doi:10.1371/journal.pone.0034173.g006
IGF-1 Receptor and Graves’ Disease
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e34173implicate ADAM17 in the trafficking of this receptor. Fig. 7
contains the aggregate concept for how this non-canonical
pathway for IGF-1R activity might explain the induction of IL-
16 and RANTES by IGF-1 that occurs in a GD-specific pattern.
The EGFR pathway also has been shown previously to be
influenced by ADAM17 activity [28]. Specifically, the release and
activation of multiple EGFR ligands is dependent on ADAM10
and ADAM17 [54]. These enzymes may play similar roles in IGF-
1R activation and signaling. It is possible that the apparently high
abundance of ADAM17 in GD orbital fibroblasts could explain, at
least in part, the peculiar actions of IGF-1 and GD-IgG actions in
these cells. Immediately following the initial submission of this
paper, Sarfstein and colleagues reported that IGF-1R can
translocate to the nucleus of breast cancer cells [55]. In so doing,
the receptor can autoregulate IGF-1R gene expression by acting as
a transcription factor. This potentially exciting set of findings may
relate to the events outlined in the current communication.
Our current findings identify a heretofore unrecognized
molecular signature displayed by GD orbital fibroblasts that
appears to distinguish them from fibroblasts coming from healthy
donors. Coupled with our recent observation that IGF-1Rb forms
a physical and functional complex with TSHR [25], the receptor
can be implicated in complex processes associated with autoim-
mune orbital disease. Recognition of aberrant nuclear trafficking
of IGF-1Ra in a disease-specific manner should allow examination
of potentially important questions concerning its role in the
pathogenesis of GD.
Materials and Methods
Materials
IGF-1R-blocking mAb 1H7 was obtained from BD Pharmingen
(San Diego, CA). rhIGF-I was purchased from R&D Systems
(Minneapolis, MN) or Calbiochem (San Diego, CA). Des (1–3)
IGF-I was obtained from GroPep (Adelaide, Australia). TAPI-1
was from EMD Chemicals (Gibbstown, NJ). NVP-AEW541was
generously provided by Novartis. Dexamethasone (1, 4 pregna-
dien-9-fluoro-16a-methyl-11b,17a, 21-triol-3,20-dione) and insu-
lin were purchased from Sigma-Aldrich (St. Louis, MO).
Polyclonal anti-IGF-1Ra and an anti-c-Jun Abs were from Santa
Cruz Biotechnology (Santa Cruz, CA) while mAbs against IGF-
1Ra and anti-Grb2 Abs were from US Biological, Swampscott,
MA. Anti-IR mAb was supplied by Invitrogen (Camarillo, CA).
Goat anti-rabbit secondary Ab conjugated with FITC and
mounting medium containing propidium iodide (PI) or DAPI
were obtained from VECTOR Laboratories (Burlingame, CA).
Goat anti-rabbit secondary Ab conjugated with Oregon Green
and goat anti-mouse secondary Ab conjugated with Texas-red
were from Molecular Probes (Carlsbad, CA).
IgG preparation
Sera were collected from patients with GD, either without or
with clinical TAO, and from individuals without known thyroid
disease (controls). Sera from a total of 3 patients with GD were
used, and the diagnosis of GD was confirmed using clinical and
laboratory-testing criteria as described previously [13]. These
activities were approved by the Institutional Review Boards of the
UCLA Center for Health Sciences, the Harbor-UCLA Medical
Center, and the University of Michigan Health Care System.
Written consent from all participants was obtained. IgG was
prepared by protein A affinity chromatography [56].
Cell culture
Human orbital fibroblasts were obtained from 6 individuals
with GD and from 4 donors without known thyroid disease.
Strains were initiated and propagated as described previously [57].
They were rigorously characterized and were free from contam-
ination with smooth muscle, endothelial, and epithelial cells [58].
They exhibited a very stable phenotype and were utilized for
experiments between the 2
nd and tenth passage from strain
initiation.
For microscopy, fibroblasts were cultured on rat-tail collagen
type 1 (BD Biosciences, Two Oak Park, MA)-treated cover glass in
DMEM containing 10% FBS, antibiotics, and glutamine. Cells
were passaged by gentle treatment with trypsin/EDTA in PBS
and allowed to attach for 24 hours. They were then shifted to
DMEM containing 1% FBS overnight. At least 2 h prior to other
treatments, some cultures received dexamethasone (10 nM), IGF-
1Ra-blocking mAb, 1H7 (5 mg/ml), NVP-AEW541 (0.5 m M), or
TAPI-1 (50 mM). They were then treated with nothing (control),
IGF-1 (10 nM), control IgG (15 mg/ml) or GD-IgG (15 mg/ml) for
the times indicated in the figure legends.
Immunofluorescence and confocal imaging analysis
Immunofluorescence staining and confocal microscopy were
performed as described previously [59]. Briefly, following the
treatment periods specified, glass coverslips were fixed in 2%
paraformaldehyde in PBS for 30 minutes and permeated with
0.2% Triton-X 100 for 30 minutes. These were then rinsed with
PBS three times and incubated with the primary rabbit anti-IGF-
1Ra mAb (1:100) or anti-IGF-1Rb (1:100) Ab in PBST containing
5% goat serum for 2 hours. Subsequently, cover slips were rinsed
with PBS and incubated with goat anti-rabbit secondary Ab
conjugated with FITC (VECTOR) or Orgeon Green (Molecular
Probe) for 45 minutes. Coverslips were rinsed extensively with
PBS and mounted on glass slides with Vectashield mounting
medium containing propidium iodide (VECTOR). Fibroblast
images were acquired and analyzed using a Nikon Eclipse 800
microscope and a Nikon PCM 2000 two laser confocal system
from Nikon Bioscience (Melville, NY). Some of the images were
captured with a Zeiss Axioskop 40 microscope/AxioCamHRc
camera. Average grey color intensity of nuclei was quantified
randomly from at least 10 nuclei in each treatment group.
Figure 7. Schematic representation of the proposed transloca-
tion of IGF-1R. ADAM 17 acts to shed IGF-1R into fragments. IGF-1Rb
complexes with TSHR. IGF-1Ra translocates to the cell nucleus where it
accumulates adjacent to chromatin. We hypothesize that it acts as a
transcription factor, accounting for some of the cell responses peculiar
to fibroblasts from patients with GD.
doi:10.1371/journal.pone.0034173.g007
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Dissociated GD or control fibroblasts were bound by FITC-
labeled anti-IGF-1Ra Ab for 30 minutes at 4uC and analyzed on a
FACScan Flow Cytometer (BD BioSciences, San Diego, CA) as
described in detail [23–25].
Sub-cellular fractionation
Fibroblasts were shifted to DMEM without serum for 24 hours
and then treated for 16 hours with IGF-1 (10 nM) or GD-IgG
(15 mg/ml). Cellular fractionation was performed according to the
protocol supplied with the NE-PER nuclear and cytoplasmic
extraction reagents (Pierce, Rockford, IL). Fractions were boiled
with SDS sample buffer, subjected to 7% SDS-PAGE, transferred
to Immobilon-P membrane (Millipore, Billerica, MA) and probed
as indicated with primary Abs followed by HRP-conjugated
secondary Abs. Membranes were treated with ECL reagent
(Amersham, Piscataway, NJ) and exposed to X-ray film (Pierce).
Chemical cross-linking
Constant numbers of fibroblasts were seeded on to 100 mm in
diameter tissue culture dishes and allowed to proliferate in DMEM
without FBS for 24 hours. Plates were cooled and ice-cold DMEM
containing
125I-IGF-1(1 mCi/ml) (ICN, Costa Mesa, CA)) was
added for 30 minutes at 4uC. Medium was removed and either
2 mM Disuccinimidyl suberate (DSS) or 2 mM Bis(sulfosuccini-
midyl suberate) (BS) (Pierce) in PBS was added to the dishes.
Monolayers were incubated for 30 minutes at 4uC, washed, and
DMEM without FBS was added for 16 hours. Cells were lysed,
fractionated, and radioactivity measured with a Cobra II auto-
gamma counter (Perkin-Elmer, Shelton, CT).
Real-time PCR and construction of IGF-1Ra/GFP fusion
adenovirus
Cellular RNA was collected, reverse transcribed and levels of
ADAM17 mRNA were determined by real-time PCR as described
previously [60]. The following primers: Forward 59-
GTTGGGTCTGTCCTGGTTTTC- 39 and reverse 59-
GTCCATTCTCTGGTGGTCCAG- 39.
An adenovirus containing the IGF-1Ra/GFP fusion protein,
designated Ad-IGF-1Ra-GFP, was generated. Cellular RNA was
purified from lysed orbital fibroblasts using RNA reagent from
Biotecx (Houston, TX). RNAs were reverse-transcribed into
cDNAs using an Omniscript RT kit (Qiagen, Valencia, CA).
These cDNAs were utilized as templates for the PCR reaction to
clone a fragment of IGF-1Ra. Primers used for the PCR were:
forward 59-GAATGAAGTCTGGCTCCGGAGG-39 and reverse
59-CTCTCCGCTTCCTTTCAGGTC-39. The resulting 2.1 kb
PCR fragment was TA cloned into pCR2.1 vector (Invitrogen,
Carlsbad, CA) and further sub-cloned in-frame into a pEGFP-N1
vector (BD Biosciences, Franklin Lakes, NJ). This cDNA fragment
was fused in-frame with GFP located positioned at the 39 end,
resulting in the generation of pEGFP-IGF-1Ra-GFP. To create an
adenoviral expression vector containing IGF-1Ra and GFP, BD
Adeno-X expression system 1 (Clontech) was utilized. IGF-1Ra–
GFP fusion fragment was retrieved by cutting pEGFP-IGF-1R-
GFP with NheI and ligated to the pshuttle2 vector. This plasmid
was then cleaved with PI-SceI and I-CeuI. The IGF-1Ra–GFP
fragment was ligated with Adeno-X viral vector, linearized with
PacI, and used to transfect low-passage HEK 293 cells. CPE
(Cytopathic effect) was evident 1 to 2 weeks after transfection.
Cells with IGF-1Ra–GFP expression were visualized in green
color. Viral particle-containing lysate was harvested by freeze-
thawing cells and stock was used to infect fibroblasts with an m.o.i.
of at least 100.
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